Related Experiment Video
Updated: Apr 2, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
[Castleman's disease: Rapid desensitization for hypersensitivity reaction to rituximab]
Introduction:
Rapid desensitization allows secure administration of a drug and is indicated when there is no therapeutic alternative.
Case Report:
We report a 49-year-old patient who presented with a hypersensitivity reaction following an infusion of rituximab (375mg/m(2)) in the context of a Castleman's syndrome. After a clinical flare (splenomegaly, adenopathies) despite treatment with tocilizumab, anakinra and valganciclovir, the reintroduction of rituximab was decided, according to the rapid desensitization protocol. Four full dose desensitizations were successfully performed allowing immediate clinical improvement (apyrexia, loss of sweating and lymphadenopathy, splenomegaly partial regression) and biological (negativation of HHV8 viral load, and disappearance of neutropenia, anemia and thrombocytopenia).
Conclusion:
Rapid desensitization is a promising method for the pursuit of rituximab therapy after a hypersensitivity reaction and should be considered in patients with no acceptable therapeutic alternative.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Hypersensitivity Reactions: Immune-Complex Reactions
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Allergic Reactions: Anaphylaxis
Allergic Reactions
Hypersensitivity Reactions: Cytolytic Reactions